✦ LIBER ✦

The FDA guidance for industry on PROs: the point of view of a pharmaceutical company

✍ Scribed by Fabio Arpinelli; Francesco Bamfi

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Feedback on the FDA's February 2006 draf

✍ Clare Bradley 📂 Article 📅 2006 🏛 BioMed Central 🌐 English ⚖ 524 KB

A Point of View on the Species Concept

✍ Hans P. Nooteboom 📂 Article 📅 1992 🏛 International Association for Plant Taxonomy 🌐 English ⚖ 352 KB

On the applicability of dynamic oxygen c

✍ J.W. Gosselink; H. Schaper; J.P. de Jonge; W.H.J. Stork 📂 Article 📅 1987 🏛 Elsevier Science ⚖ 447 KB

PROGRESS REPORT ON THE GUIDANCE FOR INDU

✍ Lin, Karl K. 📂 Article 📅 2000 🏛 Taylor and Francis Group 🌐 English ⚖ 187 KB

PMC55 IMPACT OF THE FDA DRAFT GUIDANCE O

✍ M Mordin; M Clark; C Siersma; K Copley-Merriman; A Gnanasakthy 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB

The role of perceived risk in pricing st

✍ Estelami, Hooman; Hunt, James M.; Forman, Howard 📂 Article 📅 2006 🏛 Emerald Group Publishing Limited 🌐 English ⚖ 245 KB